Filter Results:
(926)
Show Results For
- All HBS Web
(926)
- People (2)
- News (70)
- Research (778)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
Show Results For
- All HBS Web
(926)
- People (2)
- News (70)
- Research (778)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
- March 1993
- Supplement
Burroughs Wellcome and AZT (B)
Describes Burroughs Wellcome's response to protests over the pricing of its AIDS drug AZT in September 1989. Also presents short-term reactions by government officials, AIDS activists, and investors to Burroughs Wellcome's strategy. View Details
Keywords: Ethics; Health Pandemics; Multinational Firms and Management; Price; Crime and Corruption; Risk and Uncertainty; Business Strategy; Business and Community Relations; Business and Government Relations; Business and Shareholder Relations; Pharmaceutical Industry
Emmons, Willis M., III. "Burroughs Wellcome and AZT (B)." Harvard Business School Supplement 793-114, March 1993.
- March 1997
- Teaching Note
Eli Lilly and Company: Innovation in Diabetes Care TN
By: Clayton M. Christensen and Bret J. Baird
Teaching Note for (9-696-077). View Details
Keywords: Pharmaceutical Industry
- December 1998 (Revised September 1999)
- Case
Novartis: Betting on Life Sciences
By: Ray A. Goldberg, Carin-Isabel Knoop and Srinivas Sunder
The merger of Ciba-Geigy and Sandoz produced genomic-based synergies for health care, agribusiness, and nutritional supplements. How to build on the strength of the individual divisions and provide synergies that would continue Novartis' leadership role is the question... View Details
Keywords: Mergers and Acquisitions; Business Divisions; Health Care and Treatment; Leadership; Product Positioning; Science-Based Business; Corporate Strategy; Pharmaceutical Industry
Goldberg, Ray A., Carin-Isabel Knoop, and Srinivas Sunder. "Novartis: Betting on Life Sciences." Harvard Business School Case 599-076, December 1998. (Revised September 1999.)
- January–February 1994
- Article
Financial Engineering at Merck
By: Timothy A. Luehrman
Luehrman, Timothy A. "Financial Engineering at Merck." Harvard Business Review 72, no. 1 (January–February 1994): 89–99.
- November 18 2004
- Article
Merck's Recall of Rofecoxib: A Strategic Perspective
By: Felix Oberholzer-Gee and Noorein Inamdar
Oberholzer-Gee, Felix, and Noorein Inamdar. "Merck's Recall of Rofecoxib: A Strategic Perspective." New England Journal of Medicine 351, no. 21 (November 18 2004): 2147–2149.
- April 1999 (Revised May 2000)
- Case
Pilgrim Drug Company
David Thomas takes his first sales management assignment and is faced with a sales rep revolt because of a possible territory reorganization. In addition, his sales division is performing well below the national average. Rewritten version of an earlier case. View Details
Burton, M. Diane, and Jeffrey L. Bradach. "Pilgrim Drug Company." Harvard Business School Case 499-062, April 1999. (Revised May 2000.)
- February 26, 2003
- Article
Consumers' Reports on the Health Effects of Direct-To-Consumer Drug Advertising
By: Joel S. Weissman, David Blumenthal, Alvin J. Silk, Kinga Zapert, Michael Newman and Robert Leitman
Weissman, Joel S., David Blumenthal, Alvin J. Silk, Kinga Zapert, Michael Newman, and Robert Leitman. "Consumers' Reports on the Health Effects of Direct-To-Consumer Drug Advertising." Health Affairs (February 26, 2003).
- 06 Mar 2012
- First Look
First Look: March 6
influential, and industry less influential, than we commonly assume. How Early Adoption Has Increased Wealth—Until Now Authors:Diego Comin and Bart Hobijn Publication:Harvard Business Review 90, no. 3 (March 2012) Abstract Societies that... View Details
Keywords: Sean Silverthorne
- 04 Apr 2022
- Research & Ideas
Tech Hubs: How Software Brought Talent and Prosperity to New Cities
period. Software is penetrating other industries, Kerr notes. Take vaccines. Pharmaceutical companies’ speedy development of mRNA-based vaccines for COVID-19 required software, he notes. “Their capacity to bring a substantial software, AI... View Details
Keywords: by Rachel Layne
- 30 Apr 2001
- Research & Ideas
Entering the Age of Alliances
competencies of each partner and create two-way value is evidenced by, among others, the collaboration between The College Fund (UNCF) and Merck. UNCF, the largest and oldest minority educational assistance organization in the United States, and Merck, a leading global... View Details
Keywords: by James Austin
- 17 Sep 2001
- Research & Ideas
Why E-commerce Didn’t Die With the Fall of Webvan
intimacy, and community offered by direct-to-consumer marketing will have an impact on every industry and intermediary," Deighton predicted. Supermarkets may have "dodged a bullet" for now, but direct-to-consumer marketing... View Details
- 09 Jan 2007
- First Look
First Look: January 9, 2007
Communications Equipment Industry Harvard Business School Case 107-025 Purchase this case: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=107025 Symantec vs. McAfee: Competing in the Consumer Anti-virus View Details
Keywords: Martha Lagace
- Research Summary
Overview
I am interested in the individual experience of learning in organizational settings, particularly how employees learn to learn from the challenging work they do.
I am currently researching the role of reflection for raising awareness of learning opportunities that... View Details
- January 2023
- Teaching Note
The Opioid Settlement and Executive Pay at AmerisourceBergen
By: Suraj Srinivasan and Li-Kuan Ni
Teaching Note for HBS Case No 122-014. In 2020, AmerisourceBergen Corporation, a Fortune 50 company in the drug distribution industry, agreed to settle thousands of lawsuits filed nationwide against the company for its opioid distribution practices that critics alleged... View Details
Keywords: Opioids; Shareholder Activism; Investment Activism; Corporate Accountability; Corporate Governance; Governance Compliance; Governance Controls; Executive Compensation; Risk Management; Corporate Social Responsibility and Impact; Business and Shareholder Relations; Business and Stakeholder Relations; Distribution Industry; Distribution Industry; Distribution Industry; United States; West Virginia; Tennessee; Ohio; Pennsylvania
- Article
Internal Deadlines, Drug Approvals, and Safety Problems
By: Lauren Cohen, Umit Gurun and Danielle Li
Absent explicit quotas, incentives, reporting, or fiscal year-end motives, drug approvals around the world surge in December, at month-ends, and before respective major national holidays. Drugs approved before these informal deadlines are associated with significantly... View Details
Keywords: Health; Economics; Government and Politics; Innovation and Invention; Research; Science; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry
Cohen, Lauren, Umit Gurun, and Danielle Li. "Internal Deadlines, Drug Approvals, and Safety Problems." American Economic Review: Insights 3, no. 1 (March 2021): 67–82.
- September 2019
- Case
Bill & Melinda Gates Foundation: Shaping the Vaccine Manufacturing Ecosystem
By: Willy C. Shih
Vaccines for children has been a long-standing focus for the Bill & Melinda Gates Foundation, and its critical role in public health made its production an important economic and political issue. This case describes the Foundation's investment in a breakthrough vaccine... View Details
Keywords: Vaccine; Production; Supply Chain; Product; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Belgium
Shih, Willy C. "Bill & Melinda Gates Foundation: Shaping the Vaccine Manufacturing Ecosystem." Harvard Business School Case 620-021, September 2019.
- March 2010 (Revised May 2012)
- Case
Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration
By: Karim R. Lakhani and Paul R. Carlile
This case presents the Myelin Repair Foundation's accelerated research collaboration model for drug discovery. It highlights the challenges of building a multi-disciplinary and multi-institutional research collaboration that is attempting to create a treatment for... View Details
Keywords: Research and Development; Intellectual Property; Risk and Uncertainty; Strategic Planning; Collaborative Innovation and Invention; Health Disorders; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Lakhani, Karim R., and Paul R. Carlile. "Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration." Harvard Business School Case 610-074, March 2010. (Revised May 2012.)
- 24 Jan 2012
- First Look
First Look: Jan. 24
This chapter proposes a new lens to understand corruption, using internal records collected from firms that pay bribes. We examine widespread corruption in three industries in an Asian developing country: procurement, View Details
Keywords: Sean Silverthorne
- February 1999
- Teaching Note
Wegmans Food Markets: Diabetes Counseling TN
By: David E. Bell
Teaching Note for (9-599-057). View Details
- 03 Jan 2017
- First Look
January 3, 2017
January 2017 Journal of Financial Economics The Unintended Consequences of the Zero Lower Bound Policy By: Di Maggio, Marco, and Marcin Kacperczyk Abstract—We study the impact of the zero lower bound interest rate policy on the industrial... View Details
Keywords: Carmen Nobel